oNKo 001
Alternative Names: oNKo-001Latest Information Update: 11 Mar 2024
At a glance
- Originator oNKo-innate
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 27 Feb 2024 oNKo 001 is available for licensing as of 27 Feb 2024. https://www.onko-innate.com/partnerships
- 27 Feb 2024 Early research in Solid tumours in Australia (Parenteral) before February 2024 (oNKo innate pipeline, February 2024)